Last reviewed · How we verify

silevertinib in combination with temozolomide

Black Diamond Therapeutics, Inc. · Phase 2 active Small molecule

silevertinib in combination with temozolomide is a Small molecule drug developed by Black Diamond Therapeutics, Inc.. It is currently in Phase 2 development. Also known as: BDTX-1535, Temodar, TMZ.

At a glance

Generic namesilevertinib in combination with temozolomide
Also known asBDTX-1535, Temodar, TMZ
SponsorBlack Diamond Therapeutics, Inc.
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about silevertinib in combination with temozolomide

What is silevertinib in combination with temozolomide?

silevertinib in combination with temozolomide is a Small molecule drug developed by Black Diamond Therapeutics, Inc..

Who makes silevertinib in combination with temozolomide?

silevertinib in combination with temozolomide is developed by Black Diamond Therapeutics, Inc. (see full Black Diamond Therapeutics, Inc. pipeline at /company/black-diamond-therapeutics-inc).

Is silevertinib in combination with temozolomide also known as anything else?

silevertinib in combination with temozolomide is also known as BDTX-1535, Temodar, TMZ.

What development phase is silevertinib in combination with temozolomide in?

silevertinib in combination with temozolomide is in Phase 2.

Related